Investment
Features
FeesSafety
Academy
More
Pluang+

Alkane Resources extends gold-antimony mineralisation at Nagambie with high-grade drill results.

Market News
19 Oct 2026
Proactive Investors
View Source
Bullish
Alkane Resources extends gold-antimony mineralisation at Nagambie with high-grade drill results.

Alkane Resources has confirmed and extended gold-antimony mineralisation at its Nagambie Project in Victoria, including high-grade results beyond the existing resource. Recent drilling extended the C2 zone by 115 meters and revealed significant gold and antimony grades, with some intersections showing up to 17 g/t gold and 20.6% antimony. The mineralisation now shows a vertical extent of over 250 meters and broader zones outside current models, resembling Alkane's Costerfield operation. Alkane aims to earn a 60% interest by spending A$12.5 million over three years, with potential to increase to 80%. Ongoing drilling and evaluation will determine further development, with a webcast planned to discuss quarterly results.

Alkane Resources' Nagambie gold-antimony system extension is the subject here. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 20, 2026 07:11 WIB: out of 83 priced US stocks, 30 rose and 51 fell. Notable movers include ALM at USD 8.83 with a -10.17% change, FMC at USD 5.38 with a -4.95% change and a Pluang order activity of 12% Sell / 88% Buy, and CLMT at USD 55.23 with a -4.36% change and 0% Sell / 100% Buy order activity.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App